Searchable abstracts of presentations at key conferences in endocrinology

ea0031p160 | Neoplasia, cancer and late effects | SFEBES2013

Adjuvant use of 131I-MIBG in phaeochromocytoma and paraganglioma at high risk of malignancy

Rutherford Matthew A , Rankin Alastair , Yates Michael , Reed Nicholas , Freel E Marie

Phaeochromocytomas (Phaeo) and paragangliomas (PGL) are rare catecholamine producing tumours. It can be difficult to predict their malignant potential and patients can sometimes present with metastatic disease many years after their original diagnosis (1). Therefore, we offer a single dose of adjuvant 131I-Metaiodobenzylguanidine (131I-MIBG) to subjects felt to be at higher risk of local recurrence (demonstration of capsular or vascular invasion on pathol...